Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus

Clinical Cancer Research

Volumn 18, Issue 11, 2012, Pages 3188-3196

  Lee, Chee Khoon ^a   Marschner, Ian C ^a,b   Simes, R John ^a   Voysey, Merryn ^a,d   Egleston, Brian ^e   Hudes, Gary ^e   De Souza, Paul ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

^c UNIVERSITY OF WESTERN SYDNEY   (Australia)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; GLUCOSE; RECOMBINANT ALPHA2A INTERFERON; TEMSIROLIMUS; TRIACYLGLYCEROL;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; CARCINOMA, RENAL CELL; CHOLESTEROL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SIROLIMUS; TRIGLYCERIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 84861768887     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3137     Document Type: Article

References (37)

1. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, et al. Regulation of hypoxia-inducible factor 1{alpha} expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22: 7004-14.
2. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003;4:147-58. (Pubitemid 37045363)
3. Kaelin WG. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004;10:6290S-5S.
4. Tee AR, Blenis J. mTOR, translational control and human disease. Semin Cell Dev Biol 2005;16:29-37. (Pubitemid 40126874)
5. Kim WY, Kaelin WG. Role of VHL gene mutation inhuman cancer. J Clin Oncol 2004;22:4991-5004. (Pubitemid 46646218)
6. Tokunaga C, Yoshino K, Yonezawa K. mTOR integrates amino acidand energy-sensing pathways. Biochem Biophys Res Commun 2004;313:443-6. (Pubitemid 37543606)
7. Fujita S, Dreyer HC, Drummond MJ, Glynn EL, Cadenas JG, Yoshizawa F, et al. Nutrient signalling in the regulation of human muscle protein synthesis. J Physiol 2007;582:813-23. (Pubitemid 47040563)
8. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 2010;7:277-85.
9. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-30. (Pubitemid 44050136)
10. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-84. (Pubitemid 43199434)
11. Ciuffreda L, DiSanza C, Incani UC, Milella M. Them TOR pathway: a new target in cancer therapy. Curr Cancer Drug Targets 2010;10:484-95.
12. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81. (Pubitemid 46849157)
13. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a doubleblind, randomised, placebo-controlled phase III trial. Lancet 2008;372: 449-56.
14. Kasiske BL, De Mattos A, Flechner SM, Gallon L, Meier-Kriesche HU, Weir MR, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008;8:1384-92. (Pubitemid 351989497)
15. Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, et al. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res 2009;15:1428-34.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16. (Pubitemid 30099779)
17. Diggle P, Heagerty P, Liang K-Y, Zeger S. Analysis of longitudinal data. 2nd ed. London, UK: Oxford University Press; 2002.
18. Cox DR. Regression models and life-tables. J R Stat Soc Ser B 1972;34:187-220.
19. Snapinn SM, Jiang Q, Iglewicz B. Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimator. Am Stat 2005;59:301-7. (Pubitemid 41616828)
20. Kersten S. Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep 2001;2:282-6. (Pubitemid 32401521)
21. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-74. (Pubitemid 46962095)
22. Laplante M, Sabatini DM. An emerging role of mTOR in lipid biosynthesis. Curr Biol 2009;19:R1046-52.
23. Wang BT, Ducker GS, Barczak AJ, Barbeau R, Erle DJ, Shokat KM. The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile. Proc Natl Acad Sci U S A 2011;108:15201-6.
24. Xu J, Dang Y, Ren YR, Liu JO. Cholesterol trafficking is required for mTOR activation in endothelial cells. Proc Natl Acad Sci U S A 2010;107:4764-9.
25. Aggarwal D, Fernandez ML, Soliman GA. Rapamycin, an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs. Metabolism 2006;55:794-802.
26. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol 2005;23:5294-304. (Pubitemid 46206983)
27. Baker SG. Surrogate endpoints: wishful thinking or reality? J Natl Cancer Inst 2006;98:502-3. (Pubitemid 43898811)
28. Fleming TR, Prentice RL, Pepe MS, Glidden D. Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. Stat Med 1994;13:955-68. (Pubitemid 24141115)
29. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-40. (Pubitemid 19105891)
30. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000;1:49-67.
31. Gail MH, Pfeiffer R, van Houwelingen HC, Carroll RJ. On meta-analytic assessment of surrogate outcomes. Biostatistics 2000;1:231-46. (Pubitemid 33213533)
32. Daniels MJ, Hughes MD. Meta-analysis for the evaluation of potential surrogate markers. Stat Med 1997;16:1965-82. (Pubitemid 27397267)
33. Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007;25:5218-24. (Pubitemid 350232253)
34. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005;23:8664-70. (Pubitemid 46211509)
35. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4. (Pubitemid 41258223)
36. Roudier E, Mistafa O, Stenius U. Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs. Mol Cancer Ther 2006;5: 2706-15. (Pubitemid 44848997)
37. Paajarvi G, Roudier E, Crisby M, Hogberg J, Stenius U. HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage. FASEB J 2005;19:476-8. (Pubitemid 40316555)